Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Sequential interferon-alpha 2b, interleukin-2 and fotemustine for patientswith metastatic melanoma
Autore:
Terheyden, P; Becker, JC; Kampgen, E; Brocker, EB;
Indirizzi:
Univ Wurzburg, Dept Dermatol, D-97080 Wurzburg, Germany Univ Wurzburg Wurzburg Germany D-97080 rmatol, D-97080 Wurzburg, Germany
Titolo Testata:
MELANOMA RESEARCH
fascicolo: 5, volume: 10, anno: 2000,
pagine: 475 - 482
SICI:
0960-8931(200010)10:5<475:SI2IAF>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
ADVANCED MALIGNANT-MELANOMA; MULTICENTER PHASE-II; CEREBRAL METASTASES; BRAIN METASTASES; UVEAL MELANOMA; SURVIVAL; CHEMOTHERAPY; TRIAL; DACARBAZINE; THERAPY;
Keywords:
biological response modifiers; brain metastases; melanoma; nitrosourea;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Becker, JC Univ Wurzburg, Dept Dermatol, Josef Schneider Str 2, D-97080 Wurzburg, Germany Univ Wurzburg Josef Schneider Str 2 Wurzburg Germany D-97080 y
Citazione:
P. Terheyden et al., "Sequential interferon-alpha 2b, interleukin-2 and fotemustine for patientswith metastatic melanoma", MELANOMA RE, 10(5), 2000, pp. 475-482

Abstract

The aim of this study was the evaluation of both the antitumour activity and toxicity of an immunochemotherapeutic regimen consisting of interferon-alpha 2b and interleukin-2 in combination with fotemustine for patients withmetastatic melanoma. To improve the penetration of fotemustine into the brain, it was given immediately after immunotherapy, when the blood-brain barrier is still disturbed. Of the 19 patients treated, three complete remissions (CRs) and one partial remission (PR) were induced, giving an objective response rate of 21% (95% confidence interval 6-46%). The durations of the CRs were 9, 19 and 44 months; the PR lasted for 59+ months. The overall survival times for the patients with CR were 21, 25 and 70+ months, and 59+ months for the PR. For nine patients (47%, 95% confidence interval 24-71%) disease was stabilized for a median period of 8 months (range 2-18 months), resulting in a median survival of 18 months (range 10-41+ months). No haematological toxicity of World Health Organization grade 3 or more was observedand in general toxicity was low. In summary, this immunochemotherapy regimen led to long-term survival in occasional patients, and about half of the patients achieved stable disease, with prolonged treatment- and progression-free survival compared with nonresponding patients. The occurrence of brain metastases, however, was not prevented, and in fact was the site of recurrence in those patients achieving a CR. Due to its low toxicity, this protocol can be applied at a community hospital level. (C) 2000 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/10/20 alle ore 05:03:43